160 related articles for article (PubMed ID: 31814199)
1. Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study.
Kim SI; Choi CH; Kim K; Hong DH; Park JY; Kwon BS; Lee KH; Hong DG; Shin SJ; Park SI; Kim YH; Lee SH; Lee S; Hong JH; Lee JY; Kim YB; No JH; Suh DH
J Obstet Gynaecol Res; 2020 Feb; 46(2):337-346. PubMed ID: 31814199
[TBL] [Abstract][Full Text] [Related]
2. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
3. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.
Park JY; Park SK; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
Gynecol Oncol; 2011 Aug; 122(2):255-9. PubMed ID: 21565389
[TBL] [Abstract][Full Text] [Related]
4. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
[TBL] [Abstract][Full Text] [Related]
5. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome affected by tumor morcellation in unexpected early uterine leiomyosarcoma.
Lin KH; Torng PL; Tsai KH; Shih HJ; Chen CL
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):172-7. PubMed ID: 25951723
[TBL] [Abstract][Full Text] [Related]
7. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation.
Raine-Bennett T; Tucker LY; Zaritsky E; Littell RD; Palen T; Neugebauer R; Axtell A; Schultze PM; Kronbach DW; Embry-Schubert J; Sundang A; Bischoff K; Compton-Phillips AL; Lentz SE
Obstet Gynecol; 2016 Jan; 127(1):29-39. PubMed ID: 26646120
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
9. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
10. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
12. Uterine morcellation and survival in uterine sarcomas.
Bretthauer M; Goderstad JM; Løberg M; Emilsson L; Ye W; Adami HO; Kalager M
Eur J Cancer; 2018 Sep; 101():62-68. PubMed ID: 30025231
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
[TBL] [Abstract][Full Text] [Related]
14. [A clinical analysis of 153 uterine sarcomas].
Bai P; Sun J; Chao H
Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):163-7. PubMed ID: 9596892
[TBL] [Abstract][Full Text] [Related]
15. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Surgery and HIPEC as a Treatment Option for Laparoscopic Resection of Uterine Leiomyosarcoma with Morcellation: Early Results.
Sugarbaker P; Ihemelandu C; Bijelic L
Ann Surg Oncol; 2016 May; 23(5):1501-7. PubMed ID: 26545375
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of adjuvant chemotherapy and vaginal brachytherapy with or without pelvic radiation for surgical stage I-II uterine serous carcinoma.
Robbins JR; Siddiqui MS; Al-Wahab Z; Laser B; Lu M; Ali-Fehmi R; Munkarah A; Elshaikh MA
Eur J Gynaecol Oncol; 2012; 33(5):449-54. PubMed ID: 23185785
[TBL] [Abstract][Full Text] [Related]
18. Effects of morcellation on long-term outcomes in patients with uterine leiomyosarcoma.
Nemec W; Inwald EC; Buchholz S; Klinkhammer Schalke M; Gerken M; Ortmann O
Arch Gynecol Obstet; 2016 Oct; 294(4):825-31. PubMed ID: 27105972
[TBL] [Abstract][Full Text] [Related]
19. Uterine leiomyosarcoma: analysis of treatment failures and survival.
Gadducci A; Landoni F; Sartori E; Zola P; Maggino T; Lissoni A; Bazzurini L; Arisio R; Romagnolo C; Cristofani R
Gynecol Oncol; 1996 Jul; 62(1):25-32. PubMed ID: 8690287
[TBL] [Abstract][Full Text] [Related]
20. Leiomyosarcoma of uterus: a review of 14 cases.
Yu KJ; Ho DM; Ng HT; Chao KC; Kan YY
Zhonghua Yi Xue Za Zhi (Taipei); 1989 Aug; 44(2):109-14. PubMed ID: 2819573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
